Navigation Links
Synthetech Announces New Director of Manufacturing
Date:9/30/2008

ALBANY, Ore., Sept. 30 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) announced today the appointment of Dr. Frederic Farkas as Director of Manufacturing effective on October 1, 2008. Since May 2008, Dr. Farkas has provided consulting services to Synthetech. Dr. Farkas has over 13 years' experience with amino acid derivatives, peptides and API manufacturing from previous positions in manufacturing and supply chain management at Bachem Corporation, Novartis AG and Senn Chemicals Company, where he most recently served as Director of Manufacturing. Dr. Farkas earned a Bachelor of Science degree in Chemistry and a Doctor of Philosophy, Organic Chemistry, both from University Basel in Switzerland.

"We are very pleased to have Frederic join Synthetech and contribute his production skills and knowledge," stated Dr. Gregory R. Hahn, President and CEO. "Frederic brings extensive manufacturing management experience from both the pharmaceutical and fine chemical industries."

"I am pleased with the opportunity to improve production performance and continue the turnaround efforts at Synthetech," said Dr. Farkas. "Synthetech has developed an excellent reputation in unnatural amino acids, peptide chemistry and multi-step chiral organic synthesis. I am eager to build on Synthetech's strengths and look forward to meeting the challenge of improving manufacturing efficiencies and costs. I also look forward to working with the Synthetech team to meet both the short- and long-term challenges at Synthetech."

About Synthetech

Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.

MORE INFORMATION: Web site: http://www.synthetech.com

E-mail: investor@synthetech.com

CONTACT: Gary Weber, CFO

PO Box 646

Albany, Oregon 97321

541 967-6575


'/>"/>
SOURCE Synthetech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetech Announces Fiscal 2008 Results
2. Synthetech Earns National Recognition for Performance Improvement Program
3. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
4. Biotel Announces Record Revenues and Earnings for Fiscal 2008
5. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
6. Helix BioPharma Announces $11.4 Million Private Placement
7. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
8. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
9. Nomad Bioscience Announces Broad License Agreement
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
11. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, is ... is now gaining interest from Silicon Valley. “It was satisfying to complete the due ... say that, “We expect interest to continue to rise as AxioMed completes its cleanroom ...
(Date:12/9/2016)... Portage Biotech Inc. ("Portage" or "the Company") (OTC: PTGEF, ... Biohaven has issued today the following press release: ... Dec 9, 2016 - Biohaven Pharmaceutical Holding Company Ltd. ... Food and Drug Administration ("FDA") has granted the Company,s ... an orally dissolving tablet being developed for the treatment ...
(Date:12/8/2016)... La Jolla, CA (PRWEB) , ... December 08, 2016 , ... ... that 2016 was a banner year for team building events, new program offerings and ... focus, which it expanded earlier this year to include groups of over 30 people. ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
Breaking Biology Technology:
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... 2016  xG Technology, Inc. ("xG" or the "Company") ... communications for use in challenging operating environments, announced its ... Management will hold a conference call to discuss these ... Time (details below). Key Recent Accomplishments ... binding agreement to acquire Vislink Communication Systems. The purchase ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):